D0816L00003/ LYN 201: LIGHT STUDY: Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy
Study of Drug in Patients with Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer who Have Received Prior Chemotherapy
Sponsor: AstraZeneca
Enrolling: Female Patients Only
IRB Number: AAAR1227
U.S. Govt. ID: NCT02983799
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: The LIGHT study is a clinical research study for women who have been diagnosed with ovarian cancer. The purpose of the study is to evaluate the safety and effectiveness of an investigational drug in women with this type of cancer, using genetic information to evaluate tumors.
This study is closed
Investigator
Jason Wright, MD
Do You Qualify?
Are you a woman who is 18 years of age or older? Yes No
Have you been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE